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Abstract
Ninety-four common genetic variants are confirmed to be associated with breast cancer.
This study tested the hypothesis that breast cancer susceptibility variants may also be asso-
ciated with chemotherapy-induced toxicity through shared mechanistic pathways such as
DNA damage response, an association that, to our knowledge, has not been previously
investigated. The study included breast cancer patients who received neoadjuvant/adjuvant
chemotherapy from the Pharmacogenetic SNPs (PGSNPS) study. For each patient, a
breast cancer polygenic risk score was created from the 94 breast cancer risk variants, all
of which were genotyped or successfully imputed in PGSNPS. Logistic regression was per-
formed to test the association with two clinically important toxicities: taxane- related neurop-
athy (n = 1279) and chemotherapy-induced neutropenia (n = 1676). This study was well
powered (96%) to detect associations between polygenic risk score and chemotherapy
toxicity. Patients with high breast cancer risk scores experienced less neutropenia com-
pared to those with low risk scores (adjusted p-value = 0.06). Exploratory functional path-
way analysis was performed and no functional pathways driving this trend were identified.
Polygenic risk was not associated with taxane neuropathy (adjusted p-value = 0.48). These
results suggest that breast cancer patients with high genetic risk of breast cancer, conferred
by common variants, can safely receive standard chemotherapy without increased risk of
taxane-related sensory neuropathy or chemotherapy-induced neutropenia and may experi-
ence less neutropenia. As neutropenia has previously been associated with improved
PLOSONE | DOI:10.1371/journal.pone.0158984 July 8, 2016 1 / 13
a11111
OPEN ACCESS
Citation: Dorling L, Kar S, Michailidou K, Hiller L,
Vallier A-L, Ingle S, et al. (2016) The Relationship
between Common Genetic Markers of Breast Cancer
Risk and Chemotherapy-Induced Toxicity: A Case-
Control Study. PLoS ONE 11(7): e0158984.
doi:10.1371/journal.pone.0158984
Editor: Douglas Thamm, Colorado State University,
UNITED STATES
Received: April 28, 2016
Accepted: June 25, 2016
Published: July 8, 2016
Copyright: © 2016 Dorling et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: The authors are unable
to make the study dataset publicly available due to
ethical considerations relating to the original
chemotherapy clinical trials. The data used in this
study is held by the Trial Management Group for
PGSNPS, where the original concept for this
particular analysis was designed. Any access
requires appropriate ethical approvals and would be
assessed by the Trial Management Group which
includes the respective Chief Investigators of the
clinical trials and PGSNPS. Transfer of data would
require a specific Data Transfer Agreement.
survival and may reflect drug efficacy, these patients may be less likely to benefit from stan-
dard chemotherapy treatment.
Introduction
Genome-wide association studies (GWAS) provide an empirical approach for identifying mod-
erate risk alleles for a variety of widespread complex diseases and traits. Meta-analyses of 11
breast cancer GWAS (15,748 cases and 18,084 controls) and 41 studies in the Breast Cancer
Association Consortium (BCAC) (46,785 cases and 42,892 controls) have confirmed 94 breast
cancer susceptibility loci (p-value<5 x 10−8)[1–3]. Effect sizes of each genetic locus are gener-
ally modest (OR1.34), but together they explain approximately 16% of the excess familial risk
of breast cancer. In a recent study by Mavaddat et al, a breast cancer polygenic risk score was
created using 77 breast cancer risk variants. Women in the highest 1% of the risk score were
3.6 times more likely to develop breast cancer than women in the middle quintile [4].
We have hypothesised that genetic determinants of breast cancer incidence may be associ-
ated with the risk of chemotherapy-induced toxicity. This was based on the concept that varia-
tion in genes involved in pathways such as the repair of DNA damage may be important in
both the mechanisms of tumour formation and proliferation and in the response to DNA dam-
age induced by chemotherapy. For example, cyclophosphamide is an alkylating agent used to
treat a variety of cancers including breast cancer. Cyclophosphamide interferes with DNA rep-
lication by forming intra-strand and inter-strand DNA cross-links, preventing tumour prolif-
eration. The DNA cross-link repair 1B (DCLRE1B) gene is involved in repair of inter-strand
cross-links and a common allele of this gene (rs11552449) is associated with increased risk of
breast cancer [1]. The precise functional effect of this variant is unknown but patients with this
mutation may also be less able to repair inter-strand cross-links induced in normal tissue by
cyclophosphamide during treatment for breast cancer, resulting in increased toxicity.
Further, specific mutations that influence the risk of breast cancer developing may also
affect genes in specific drug metabolism pathways. For example, it is known that polyadenosine
5’diphosphoribose polymerisation (PARP) enzymes play an important role in the repair of sin-
gle strand breaks. PARP inhibitors (PARPi) target DNA homologous repair pathways, by pre-
venting repair of single strand breaks leading to problems downstream with double strand
repair. PARPi work, therefore, in synergy with DNA damaging agents like platinums, which
also cause strand breaks. In patients with rare BRCA1 or BRCA2mutations, the already com-
promised homologous repair pathways allow PARPi to work particularly effectively leading to
“synthetic lethality” [5]. Thus, such genetic mutations both increase susceptibility to breast
cancer and enable a better response to certain treatments, although the drug toxicity profile of
patients carrying these mutations is, as yet, unclear. Variants of genes that play a role in drug
metabolism may also lie in pathways unrelated to DNA repair.
To date, chemotherapy toxicity GWAS have had limited success in identifying common
genetic variants that significantly influence a patient’s risk of toxicity [6–11]. This is mainly
due to lack of statistical power stemming from small samples and the requirement for stringent
p-value thresholds for obtaining statistical significance. No single nucleotide polymorphisms
(SNPs) reaching genome-wide significance have been independently replicated in validation
samples to accepted GWAS levels of significance.
The aim of this study was to look for associations between common genetic variants known
to increase the risk of breast cancer and chemotherapy-induced toxicity using patient samples
from the Pharmacogenetic SNPs (PGSNPS) study, one of the largest chemotherapy toxicity
Breast Cancer Risk Variants and Chemotherapy Toxicity
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GWAS to date. Common genetic variants have small individual effects on breast cancer so it is
likely that they will also have small individual effects on chemotherapy toxicity. Thus, to
increase the power to detect an association between genotype and toxicity, variants were com-
bined in a polygenic risk score. Whilst for most chemotherapeutic agents there is a presumed
mechanism of action, it is widely accepted that we do not have a complete understanding of all
the mechanisms by which the majority of the agents function. Further, the precise impact of
many of the breast cancer variants on the gene in which they lie and the mechanisms underly-
ing the individual associations between each variant and breast cancer risk are as yet unknown.
Thus, all breast cancer risk variants were included in our analyses.
Materials and Methods
Patients
The study cohort consisted of female breast cancer patients from PGSNPS, a large study that
was set up to investigate the role of germline variants in chemotherapy toxicity [12]. The
PGSNPS sample includes 2354 female patients from four UK breast cancer chemotherapy tri-
als: NEAT [13], BR9601 [13], tAnGo [14] and Neo-tAnGo [15]. S1 Table and S1 Fig (see Sup-
porting Information) summarise PGSNPS and the clinical trial regimens. In brief, patients in
NEAT and BR9601 received either six or eight cycles of cyclophosphamide, methotrexate and
5-fluouracil (CMF) or four cycles of epirubicin (E) followed by four cycles of CMF, while
patients in tAnGo and Neo-tAnGo received either four cycles of EC followed by four cycles of
paclitaxel (T) with or without gemcitabine (±G) or four cycles of T±G followed by four cycles
of T. DNA samples were collected along with demographic, tumour and treatment informa-
tion, chemotherapy toxicity scores and relapse and survival times. An additional 56 patients
who were not taking part in a clinical trial were recruited from the Cambridge University Hos-
pitals NHS Foundation Trust breast unit using the same clinical response forms. These patients
received four cycles of epirubicin (E) followed by four cycles of cyclophosphamide, methotrex-
ate and 5-fluorouracil (CMF).
Ethics and data availability
PGSNPS [Pharmacogenetics of Early Breast Cancer Chemotherapy–reference number 05/
Q0104/1] was approved by the NRES Committee East of England—Cambridge East. All partic-
ipants provided informed consent to take part in PGSNPS.
The data used in this study is held by the Trial Management Group for PGSNPS, where the
original concept for this analysis was designed. Any access requires appropriate ethical approv-
als and would be assessed by the Trial Management Group which includes the respective Chief
Investigators of the clinical trials and PGSNPS. Transfer of data would require a specific Data
Transfer Agreement.
Toxicity phenotypes
This study investigated two common and clinically important chemotherapy-induced toxici-
ties: neutropenia and taxane-related sensory neuropathy (for the purposes of this study, this
will be referred to as simply “neuropathy” from now on). For all patients, toxicity information
was collected prospectively and graded using the National Cancer Institute Common Toxicity
Criteria for Adverse Events (NCI CTCAE) version 2 or 3, depending on the clinical trial from
which the patient was recruited into PGSNPS. Rates and grades of neutropenia were recorded
in 1676 patients who received any of the trial chemotherapy regimens in NEAT, tAnGo and
Neo-tAnGo (data for neutropenia was not available from BR9601) or were not in a trial and
Breast Cancer Risk Variants and Chemotherapy Toxicity
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received E-CMF. Rates and grades of neuropathy were recorded in 1279 patients who received
a paclitaxel-containing regimen (tAnGo and Neo-tAnGo).
Genotyping, quality control and imputation
Samples were genotyped using the Affymetrix 6.0 SNP array. Quality control procedures were
applied to remove variants that were missing in>5% of samples; had minor allele frequency
(MAF)< 1%; or had MAF<5% and were missing in>1% samples. Variants were also removed
if their genotype frequencies deviated from those expected under Hardy-Weinberg equilibrium
(p-value< 10−5). Samples were removed that had>10% of all variants missing. Principle com-
ponents analysis (PCA) was used to identify and exclude individuals with non-European
ancestry and control for population substructure. Genome coverage was increased by imputa-
tion using SHAPEIT [16] and IMPUTE v2 [17] with the 1000 Genomes reference panel [18].
Genotype dosages of the breast cancer risk alleles were extracted from the imputed data.
Statistical methods
To quantify each patient’s genetic risk of breast cancer, polygenic risk scores were created by
summing the patient’s risk allele dosages across all the variants. Two risk scores were
calculated:
1. Non-weighted: risk scorei ¼
Pj
1Gi




where j = variant 1..94
βj = the per-allele log-odds ratio for risk of breast cancer associated with variant j
G = risk allele dosage
The log-odds ratios used to weight the risk score were taken directly from the report by
Mavaddat et al [4] who tested the association of each variant with breast cancer risk while
adjusting for the effect of other variants (see Table 1). Seventeen variants have been identified
since Mavaddat et al performed their analysis [2,3]. For these, the log-odds ratios used were
those reported by Michailidou et al [3].
Neutropenia and neuropathy grades were dichotomised into cases (neutropenia grade3,
neuropathy grade2) and controls (neutropenia grades 0–2, neuropathy grades 0–1) (see
Table 2). Logistic regression was used to test the association between polygenic risk score and
toxicity case status for neutropenia and neuropathy, respectively. Each of the 94 genetic vari-
ants was also tested separately for association with neutropenia and neuropathy. For multivari-
able analysis, pre-specified important non-genetic covariates were included in the models. The
neutropenia analysis was adjusted for trial and patient age and the neuropathy analysis was
adjusted for trial, pre-treatment body mass index (BMI) and the first two principle components
to control for population substructure. Per-allele odds ratios (ORs) and 95% confidence inter-
vals (CIs) are presented for the non-weighted polygenic risk score and individual variants. ORs
and CIs corresponding to a one standard deviation (SD) increase in risk score are presented for
the weighted polygenic risk score.
Pathway analysis. Interesting associations between polygenic risk and toxicity were fol-
lowed up with exploratory pathway analysis to investigate whether a subset of the breast cancer
variants, lying in a common pathway, were responsible for the observed association. The breast
cancer variants were mapped to the genes in which they lay or to the nearest gene if they were
intergenic. These variant-gene pairs were ranked using the p-value for association between
Breast Cancer Risk Variants and Chemotherapy Toxicity
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Table 1. Genetic variants known to influence risk of breast cancer.











rs616488 PEX14 1 10566215 A 1.06 0.67 0.96
rs11552449 PTPN22-BCL2L15-AP4B1-DCLRE1B-HIPK1 1 114448389 T 1.08 0.18 0.94
rs11249433 None 1 121280613 G 1.1 0.43 0.81
rs12405132 RNF115 1 145644984 C 1.05b 0.63 1
rs12048493 OTUD7B 1 149927034 C 1.07b 0.34 0.52
rs6678914 LGR6 1 202187176 G 1.01 0.40 0.99
rs4245739 MDM4 1 204518842 C 1.03 0.28 1
rs72755295 EXO1 1 242034263 G 1.15b 0.04 0.72
rs12710696 OSR1 2 19320803 A 1.04 0.37 1
rs4849887 INHBB 2 121245122 C 1.09 0.92 1
rs2016394 METAP1D-DLX1-DLX2 2 172972971 G 1.05 0.55 0.87
rs1550623 CDCA7 2 174212894 A 1.06 0.85 1
rs1045485 CASP8d 2 202149589 G 1.04 0.87 0.99
rs13387042 IGFBP5d 2 217905832 A 1.14 0.51 1
rs16857609 DIRC3 2 218296508 T 1.07 0.28 0.99
rs6762644 ITPR1-EGOT 3 4742276 G 1.07 0.41 0.99
rs4973768 SLC4A7 3 27416013 T 1.09 0.49 0.99
rs12493607 TGFBR2 3 30682939 C 1.05 0.34 0.99
rs6796502 PRSS42 3 46866866 G 1.09b 0.91 0.96
rs1053338 ATXN7 3 63967900 G 1.08b 0.15 0.99
rs9790517 TET2 4 106084778 T 1.05 0.20 0.99
rs6828523 ADAM29 4 175846426 C 1.1 0.89 1
rs10069690 TERTd 5 1279790 T 1.02 0.25 0.66
rs7726159 TERTd 5 1282319 A 1.04 0.36 0.75
rs2736108 TERTd 5 1297488 C 1.07 0.73 0.78
rs13162653 MARCH11 5 16187528 G 1.05b 0.57 0.97
rs2012709 SUB1 5 32567732 T 1.05b 0.49 0.99
rs10941679 None 5 44706498 G 1.12 0.26 0.95
rs889312 MAP3K1d 5 56031884 C 1.12 0.30 0.99
rs10472076 RAB3C 5 58184061 C 1.04 0.38 0.94
rs1353747 PDE4D 5 58337481 T 1.09 0.89 0.99
rs7707921 ATG10 5 81538046 A 1.08b 0.75 0.99
rs1432679 EBF1 5 158244083 G 1.07 0.44 0.99
rs11242675 FOXQ1 6 1318878 T 1.06 0.63 0.99
rs204247 RANBP9 6 13722523 G 1.05 0.45 1
rs9257408 None 6 28926220 C 1.05b 0.37 0.98
rs17529111 None 6 82128386 G 1.05 0.22 0.98
rs12662670 ESR1e 6 151918856 G 1.14 0.09 0.99
rs2046210 ESR1e 6 151948366 A 1.05 0.38 1
rs6964587 AKAP9 7 91630620 T 1.05b 0.40 1
rs4593472 LINC-PINT 7 130667121 C 1.05b 0.64 1
rs720475 ARHGEF5-NOBOX 7 144074929 G 1.06 0.74 1
rs9693444 None 8 29509616 A 1.07 0.35 0.99
rs13365225 KCNU1 8 36858483 A 1.05b 0.84 1
rs6472903 CASC9 8 76230301 T 1.1 0.84 0.93
rs2943559 HNF4G 8 76417937 G 1.13 0.09 1
(Continued)
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Table 1. (Continued)











rs13267382 None 8 117209548 A 1.05b 0.36 0.93
rs13281615 MYCd 8 128355618 G 1.1 0.43 0.99
rs11780156 MYCd 8 129194641 T 1.07 0.19 1
rs1011970 CDKN2A/B 9 22062134 T 1.05 0.18 0.99
rs10759243 KLF4d 9 110306115 A 1.05 0.29 1
rs865686 KLF4d 9 110888478 T 1.11 0.64 0.99
rs2380205 ANKRD16 10 5886734 C 1.02 0.57 1
rs7072776 MLLT10-DNAJC1 10 22032942 A 1.06 0.30 1
rs11814448 DNAJC1 10 22315843 C 1.22 0.02 0.98
rs10995190 NRBF2d 10 64278682 G 1.17 0.87 0.99
rs704010 ZMIZ1 10 80841148 T 1.07 0.42 1
rs7904519 TCF7L2 10 114773927 G 1.06 0.48 0.99
rs11199914 FGFR2d 10 123093901 C 1.06 0.70 0.99
rs2981579 FGFR2d 10 123337335 A 1.25 0.44 0.99
rs3817198 LSP1 11 1909006 C 1.07 0.34 1
rs3903072 DKFZp761e198-OVOLI-SNX32-CFL1-MUS81 11 65583066 G 1.06 0.56 1
rs78540526 CCND1d 11 69331418 T 1.18 0.08 0.98
rs554219 CCND1d 11 69331642 G 1.12 0.13 0.99
rs75915166 CCND1d 11 69379161 A 1.024 0.07 0.95
rs11820646 BARX2 11 129461171 C 1.05 0.60 0.99
rs12422552 None 12 14413931 C 1.03 0.29 0.91
rs10771399 PTHLH 12 28155080 A 1.16 0.89 0.99
rs17356907 NTN4 12 96027759 A 1.1 0.72 1
rs1292011 None 12 115836522 A 1.08 0.58 1
rs11571833 BRCA2-N4BP2LI-N4BP2L2 13 32972626 T 1.26 0.01 0.99
rs2236007 PAX9-SLO25A21 14 37132769 G 1.09 0.81 0.98
rs2588809 RAD51L1 14 68660428 T 1.07 0.17 1
rs999737 RAD51L1 14 69034682 C 1.08 0.76 0.99
rs941764 CCDC88C 14 91841069 G 1.06 0.35 0.99
rs11627032 RIN3 14 93104072 T 1.06b 0.76 0.99
rs3803662 TOX3 16 52586341 A 1.23 0.30 1
rs17817449 MIRI972-2-FTO 16 53813367 T 1.08 0.61 0.99
rs11075995 FTO 16 53855291 T 1.04 0.24 0.99
rs13329835 CDYL2 16 80650805 G 1.08 0.23 0.99
rs146699004 TEFM 17 29230520 GGT 1.08b 0.81 0.87
rs6504950 COX11e 17 53056471 G 1.07 0.72 1
rs745570 CBX8 17 77781725 A 1.05b 0.50 1
rs527616 None 18 24337424 G 1.04 0.66 0.94
rs1436904 CHST9 18 24570667 T 1.06 0.60 1
rs6507583 SETBP1 18 42399590 A 1.10b 0.93 0.99
rs8170 ABHD8/ANKLE1e 19 17389704 A 1.03 0.20 0.99
rs2363956 ABHD8/ANKLE1e 19 17394124 T 1.03 0.51 0.96
rs4808801 SSBP4-ISYNA1-ELL 19 18571141 A 1.07 0.66 1
rs3760982 C19orf61-KCNN4-LYPD5-ZNF283 19 44286513 A 1.06 0.49 0.99
rs2823093 NRIP1 21 16520832 G 1.08 0.75 0.97
(Continued)
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each variant and toxicity, from most strongly to least strongly associated, regardless of the
direction of effect on toxicity. Where more than one variant mapped to the same gene, the
most significant toxicity-associated variant was used for ranking. The top 50% of the ranked
genes were entered into the Database for Annotation, Visualization and Integrated Discovery
(DAVID) version 6.7 functional annotation tool [19,20]. DAVID draws functional annotations
from various online databases to group genes that are in the same biological pathway and per-
forms a Fisher’s exact test to determine whether genes from any particular pathway are over-
represented in the user’s list of genes. A Fisher exact p-value0.05 identified pathways that
were significantly enriched among the top genes for toxicity.
Statistical Power. This study was well powered to detect significant associations between
breast cancer polygenic risk score and the toxicity endpoints examined. Assuming a 30% preva-
lence of moderate-severe toxicity (neutropenia 3, neuropathy grade2) in breast cancer
patients, the power to detect a small difference of 0.1 in mean risk score between patients with
moderate-severe toxicity and patients with no or mild toxicity, at p-value<0.05, would be 96%
in the neuropathy sample and 99% in the neutropenia sample. This difference in mean risk
score is equivalent to a relative risk of moderate-severe toxicity of 1.1 for patients with a higher
polygenic risk score.
Results
The total number of patients included in this study was 1677. Patient characteristics are sum-
marised in S2 Table (see Supporting Information). All 94 genetic variants known to increase
the risk of breast cancer were genotyped or successfully imputed (IMPUTE2 info metric>0.5)
Table 1. (Continued)











rs17879961 CHEK2 22 29121087 G 1.36 0.001 0.86
rs132390 EMID1-RHBDD3-EWSR1 22 29621477 C 1.11 0.04 0.78
rs6001930 MKL1 22 40876234 C 1.13 0.10 1
aAdjusted breast cancer odds ratios from Mavaddat et al (4)
bUnadjusted odds ratios from BCACmeta-analysis (1–3)
cMean imputation r2 from IMPUTE2 (r2 = 1 for genotyped SNPs)
dpublished target gene
eknown target gene, not yet published
Chr: chromosome.
doi:10.1371/journal.pone.0158984.t001
Table 2. Distribution of chemotherapy-induced neutropenia and taxane-related sensory neuropathy in the PGSNPS sample according to the
National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 2/3.
NCI CTCAE grade Neutropenia; total N = 1676 n (%) Neuropathy; total N = 1279 n (%)
0 733 (43.7) 271 (21.2)
1 199 (11.9) 648 (50.7)
2 245 (14.6) 304 (23.7)
3 293 (17.5) 56 (4.4)
4 206 (12.3) 0 (0)
Toxicity cases (moderate-severe toxicity) grade3 grade2
499 (29.8) 360 (28.1)
doi:10.1371/journal.pone.0158984.t002
Breast Cancer Risk Variants and Chemotherapy Toxicity
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in the PGSNPS sample. The variants and information about MAF and imputation certainty
can be found in Table 1. Fig 1 shows the approximately normal distribution of the two poly-
genic risk scores in the PGSNPS patients.
The non-weighted risk score was significantly associated with a decreased risk of neutropenia
(grade3) on univariable analysis (per-allele OR = 0.98; 95% CI = (0.96, 0.99); p = 0.04) (Table 3).
This finding was not nominally significant when adjusted for age and trial (p = 0.06) but the effect
size was the same. The weighted risk score was not significantly associated with neutropenia
(grade3) but the effect was in the same direction as with the non-weighted score. Neither the
non-weighted nor the weighted risk score was associated with neuropathy (OR = 0.99 (0.97, 1.01);
p = 0.48 and OR = 0.99 (0.95, 1.02); p = 0.47, respectively). None of the individual genetic variants
were significantly associated with neuropathy or neutropenia at the p<5 x 10−4 level.
Pathway analysis
Pathway analysis was performed to investigate whether a specific molecular pathway was driving
the trend between increased breast cancer risk and reduced risk of neutropenia. The individual
breast cancer risk variants were ranked according to their p-value for association with neutrope-
nia and the ranked variant-gene pairs were compiled to create a list of 76 genes. Table 4 shows
the top 50% (n = 38) of genes in the ranked list. The DAVID functional overrepresentation tool
[19,20] was used to annotate the top 38 genes and identified the p53 signalling pathway as the
most strongly enriched pathway (Fisher exact p-value = 0.004). Three genes (CCND1, CHEK2,
MDM4) in the p53 signalling pathway appeared in the top 38 genes. However, this observed
enrichment did not remain significant following Bonferroni correction for the multiple pathways
tested by the DAVID tool (corrected p53 signalling pathway p-value = 0.13).
Fig 1. Distribution of polygenic risk scores in the PGSNPS cohort. A) Non-weighted polygenic risk score. B)
Weighted polygenic risk score.
doi:10.1371/journal.pone.0158984.g001
Table 3. Association of polygenic risk scores with chemotherapy-related neutropenia and taxane-related sensory neuropathy.
Odds ratio (95% conﬁdence interval) & p-valuea
Non-weighted risk score Weighted risk score
unadjusted adjustedb unadjusted adjustedb
neutropenia (n = 1676) 0.98 (0.96, 0.99) p = 0.04 0.98 (0.96, 1.00) p = 0.06 0.98 (0.95, 1.01) p = 0.16 0.98 (0.95, 1.01) p = 0.20
neuropathy (n = 1279) 0.99 (0.97, 1.01) p = 0.41 0.99 (0.97, 1.01) p = 0.48 0.98 (0.95, 1.02) p = 0.37 0.99 (0.95, 1.02) p = 0.47
aNon-weighted risk score: per-allele odds ratio and conﬁdence interval; Weighted risk score: per-standard deviation odds ratio and conﬁdence interval
bNeutropenia: adjusted for age and trial; neuropathy: adjusted for body mass index, trial and ﬁrst two principle components.
doi:10.1371/journal.pone.0158984.t003
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Discussion
The hypothesis behind this study was that common genetic variants known to increase the risk
of breast cancer may also increase the likelihood of developing treatment-related toxicity
Table 4. Top 38 genes according to p-value for association between highest-ranking breast cancer risk variant and neutropenia.
Gene Breast cancer risk variant Variant association with neutropenia
Odds Ratio P-value
ZMIZ1 rs704010 1.20 0.02
KCNN4 rs3760982 0.85 0.03
MAP3K1 rs889312 1.19 0.04
DCLRE1B rs11552449 0.81 0.05
KCNU1 rs13365225 0.81 0.05
DLX2 rs2016394 0.86 0.06
ITPR1 rs6762644 1.15 0.08
MYC rs13281615 1.14 0.10
RANBP9 rs204247 1.13 0.10
CASC9a rs6472903 0.84 0.10
CBX8 rs745570 0.89 0.13
SNX32 rs3903072 0.90 0.17
SLC4A7 rs4973768 1.11 0.18
TET2 rs9790517 0.89 0.22
KLF4 rs10759243 1.10 0.23
TERT rs2736108 0.89 0.26
ANKRD16 rs2380205 0.92 0.27
CDYL2 rs13329835 0.90 0.27
NRIP1 rs2823093 0.91 0.29
CHST9 rs1436904 0.93 0.34
CCND1 rs78540526 1.14 0.37
FGFR2 rs2981579 1.07 0.37
DNAJC1 rs11814448 0.74 0.37
HNF4G rs2943559 0.88 0.38
ATXN7 rs1053338 0.91 0.38
AKAP9 rs6964587 1.07 0.38
MKL1 rs6001930 0.90 0.41
LGR6 rs6678914 1.06 0.45
FOXQ1 rs11242675 0.94 0.46
ANKLE1 rs8170 1.07 0.50
RNF115 rs12405132 0.95 0.51
SETBP1 rs6507583 1.10 0.52
ADAM29 rs6828523 0.92 0.52
NRBF2 rs10995190 0.93 0.53
ESR1 rs12662670 0.92 0.53
CHEK2 rs17879961b 1.36x10-19 0.54
PTHLH rs10771399 0.93 0.56
IGFBP5 rs13387042 0.96 0.59
MDM4 rs4245739 0.96 0.60
aCASC9 not mapped by DAVID tool so excluded from pathway analysis
bvariant frequency in PGSNPS = 0.001
p53 signalling pathway genes highlighted in bold.
doi:10.1371/journal.pone.0158984.t004
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following chemotherapy for breast cancer. In this well powered study, no evidence was found
for an association between common variants known to increase breast cancer risk and taxane-
related sensory neuropathy in the PGSNPS cohort. Interestingly, and contrary to our hypothe-
sis, there was some evidence of a relationship between carrying an increased number of breast
cancer risk alleles and decreased risk of experiencing chemotherapy-induced neutropenia
grade3 (OR = 0.98; 95% CI = (0.96, 1.00)). Weighting the alleles by the estimate of their
effect on breast cancer risk reduced the strength of this association. This suggests that the mag-
nitude of effect that these variants have on risk of neutropenia is not equal to their magnitude
of effect on risk of breast cancer. This is demonstrated in Fig 2, which shows the effects that the
individual variants have on breast cancer risk (as reported by Mavaddat et al 2015) plotted
against their effects on neutropenia in the PGSNPS sample; there is no visible relationship
between the effects. Pathway analysis did not identify any significant pathway enrichment in
the genes representing the top-ranked breast cancer risk variants.
None of the individual variants were significantly associated with chemotherapy-induced
toxicity. The original work that confirmed the association of the 94 genetic variants with breast
cancer risk was performed by BCAC and based on samples of over 100,000 patients. In con-
trast, the PGSNPS breast cohort studied in the current analysis has fewer than 2,000 patients.
Therefore, the power to detect a true association at genome-wide significance is much lower
than that of the breast cancer susceptibility studies. With an increased sample size, there would
be greater power to detect strong associations between individual variants and chemotherapy
toxicity.
The observed association between polygenic breast cancer risk and decreased neutropenia
suggests that breast cancer patients who present with a high genetic risk of breast cancer, con-
ferred by common variants, can safely receive standard chemotherapy and may experience less
neutropenia compared to patients with low genetic risk of breast cancer. There is strong evi-
dence to support the relationship between neutropenia or leukopenia and improved survival
[21–23]. Abraham et al have shown that in a cohort of over 6000 early breast cancer patients
from randomised clinical trials, those who achieved neutropenia grade3 during their treat-
ment had statistically significant improved relapse-free survival (hazard ratio = 086; 95% CI =
(076–097); p = 002) [23]. In the current study population, expanded clinical and survival
data was available for 1450 patients. After adjusting for non-genetic predictors of survival, the
29% of breast cancer patients who experienced neutropenia grade3 had longer relapse-free
Fig 2. Scatter plot comparing variant-associated odds ratios for breast cancer risk, published by the
Breast Cancer Association Consortium (BCAC), with odds ratios for neutropenia risk estimated in the
Pharmacogenetic SNPs (PGSNPS) study.
doi:10.1371/journal.pone.0158984.g002
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survival compared to the 71% who did not experience neutropenia grade3 (HR = 0.71; 95%
CI = (0.54–0.94); p = 0.02). Neutropenia may therefore be a surrogate marker of efficacy,
although the mechanisms underlying the association between neutropenia and survival are
unclear. The hypothesis that neutropenia may reflect efficacy is supported by a recent prospec-
tive randomised phase III trial of tailored and dose-dense versus standard tri-weekly adjuvant
chemotherapy for high risk breast cancer. In the tailored and dose-dense therapy arm of the
trial, where a patient had a toxicity of grade 2 or less, the chemotherapy dose was escalated.
The results of the trial showed that the tailored approach resulted in an improvement in all
studied efficacy endpoints [24].
Given the potential relationship between neutropenia and clinical outcome, the finding that
patients with high polygenic risk of breast cancer experience less neutropenia may, firstly,
reflect the fact that for some patients standard chemotherapy regimens are sub-optimal and,
secondly, suggests that genetic risk of cancer may potentially distinguish these patients, who
may tolerate more intense chemotherapy that could improve survival. If this is the case, com-
mon breast cancer risk variants may be a useful tool for predicting which patients are likely to
have poorer prognosis. We evaluated the relationship between the breast cancer risk polygenic
score and relapse-free survival in the same cohort of patients. The polygenic risk score was pre-
dictive of relapse-free survival such that patients who have an increased risk of breast cancer
(and therefore lower risk of neutropenia) tended to have shorter relapse-free survival
(HR = 1.02; 95% CI = (1.00–1.04); p = 0.06). This equates to a 23% increase in risk of relapse or
death for every 10 extra risk alleles that a patient carries (HR = 1.23; 95% CI = (0.99–1.51);
p = 0.06). This difference in hazards is illustrated in a Kaplan-Meier plot in Fig 3. After adjust-
ing for neutropenia case-control status, this relationship was weakened slightly; patients carry-
ing an extra 10 risk alleles had 21% increase in risk of relapse or death (HR = 1.216; 95% CI =
(0.98–1.49); p = 0.08). These results support the hypothesis that neutropenia is a marker of effi-
cacy of chemotherapy and that efficacy could be predicted by breast cancer polygenic risk.
However, a large study with more power to detect subtle survival effects is required to confirm
these results.
In conclusion, for breast cancer patients who are carrying common genetic variants known
to increase the risk of breast cancer, standard chemotherapy for breast cancer, although safe,
may not be adequately effective. It is likely that there are less common variants and rare muta-
tions that have large effects on toxicity response to chemotherapy and these may prove more
useful for predicting patient drug response in the clinic. Thus, targeted sequencing of candidate
Fig 3. Kaplan-Meier plot comparing relapse-free survival in patients carrying >90 risk alleles to those
carrying <80 risk alleles.
doi:10.1371/journal.pone.0158984.g003
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genes or whole-exome/genome sequencing in large patient samples should be a next step in the
search for pharmacogenetic determinants of chemotherapy toxicity.
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